Gene therapy

#Biologics #Covid-19 #Drug delivery #Gene therapy #Genetics / genomes #Immunology / Virology & Vaccines #RNA

The challenge of providing rapid, effective protection against Covid-19

Lisa Osborne, CEO at RANA Healthcare Solutions interviews Daniel Kavanagh, PhD, Senior Scientific Advisor, Gene Therapy at WCG. The Covid-19 pandemic has put vaccine development centre-stage. Never have citizens around the world been so focused on the length of time it takes to develop, test, approve, manufacture and distribute new… Read More

#Covid-19 #Exclusive Content #News

#Drug candidates #Drug delivery #Drug development #Drug discovery #Gene therapy

Ilya’s ILP100 gene therapy speeds up healing by six days on average

Clinical stage gene therapy company, Ilya Pharma, has released further results from the first in human (FIH) trial of ILP100 for treating difficult and chronic wounds. ILP100 represents a new-in-class drug candidate, engineering Limosilactobacillus reuteri bacteria to produce and release the key human chemokine CXCL12 at the wound site. After delivery, ILP100 enhances the healing properties of immune cells in the… Read More

#News

#Cell and gene therapy #Drug delivery #Gene therapy #Life sciences

£18m network of gene therapy hubs to be created in the UK

LifeArc and the Medical Research Council (MRC), with support from the Biotechnology and Biological Sciences Research Council (BBSRC), have announced three major investments totalling £18 million to create a network of gene therapy innovation hubs. The funding will support the creation of three facilities to advance the clinical development of… Read More

#Editor's Choice #News

#Drug development #Drug discovery #Gene therapy #Therapeutics

Geneticist launches Axovia Therapeutics to develop medicines for ciliopathies

Axovia Therapeutics, a gene therapy company developing disease-transformative medicines for ciliopathies, led by researcher Professor Philip Beales, has launched after being in stealth mode for the past year. Axovia is a majority-owned subsidiary of Jaguar Gene Therapy, and is partially funded by UCL Technology Fund. Axovia is receiving initial operational… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Gene therapy #Life sciences #Narrated podcasts #Stem cells

The power of precision and the potential of human tissue chips

Today’s episode is titled: The power of precision and the potential of human tissue chips, and covers 2 articles taken from the most recent issue of DDW. These articles are titled: The power of precision to keep biologics effective and safe & Why we should be interested in human tissue chips These… Read More

#Podcasts

#Biologics #Cell therapy #CRISPR #Gene therapy #Immuno-oncology

Cognate BioServices announces major US and Europe expansion

Cobra Biologics, the gene therapy division of the Cognate BioServices’ group, has announced a multi-phase expansion of its plasmid DNA services, a continuation of its gene therapy services’ project for viral vectors and plasmid DNA. This includes a four-fold increase in HQ High Quality (HQ) DNA manufacturing capacity alongside new… Read More

#News

#Cell and Gene Therapy Catapult #Cell therapy #Gene therapy

Funding to UK cell and gene therapy training centre to strengthen skills pipeline

The Cell and Gene Therapy Catapult (CGT Catapult) and Hertfordshire Local Enterprise Partnership (LEP) in the UK have announced that a new cell and gene therapy integration laboratory at the CGT Catapult facility in Stevenage will be part-funded by the government’s Getting Building Fund. The new laboratory will be exclusively… Read More

#Editor's Choice #News

#Biotechnology #Cell therapy #Covid-19 #Gene therapy #Immunology / Virology & Vaccines #Pharmaceutical

Investment banking head offers market outlook for 2021

The Jefferies Healthcare Temperature Check report is now in its third edition and published to coincide with the 11th annual Global Healthcare Conference which was held virtually. Over 500 responses from senior leaders in the sector responded for this year’s report, giving views on both the current state of the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #News #Opinion #Trends & Analysis

#Gene therapy #Pharmaceutical

CEVEC signs agreement with Roche for gene therapy technology

CEVEC Pharmaceuticals has signed an option and license agreement with Roche for the use of its newly launched ELEVECTA Technology for large scale manufacturing of adeno‐associated virus (AAV) vectors for gene therapy applications. Under the terms of the agreement, CEVEC will grant Roche, and Spark Therapeutics, a member of the… Read More

#News

#Drug development #Gene therapy

Oxford Biomedica and PhoreMost enter gene therapy discovery collaboration

Oxford Biomedica, gene and cell therapy group and PhoreMost, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed. PhoreMost will deploy its in-house expertise and next-generation phenotypic… Read More

#Editor's Choice #News

#Cell therapy #Gene therapy

Digitalising cell and gene therapies manufacturing: a case study

Lonza will be hosting a free webinar to discuss its innovative approach to digitalising the company’s cell and gene therapy manufacturing operations through the implementation of the MODA-ESTM Platform. It will take place on 17 November. In the webinar, Lonza will also outline future plans for utilising the platform to… Read More

#News

#Cell therapy #Gene therapy

Bayer acquires AskBio to broaden innovation in cell and gene therapy

Bayer has acquired Asklepios BioPharmaceutical (AskBio) a US-headquartered biopharmaceutical company specialising in the research, development and manufacturing of gene therapies across different therapeutic areas. AskBio’s development portfolio includes investigational pre-clinical and clinical stage candidates for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases. Bayer will own full… Read More

#News #Trending News

#Cell and Gene Therapy Catapult #Cell therapy #Gene therapy

High potential opportunity zone named for cell and gene therapy

The UK Department for International Trade (DIT) has classified Stevenage in the UK, as a High Potential Opportunity (HPO) zone in recognition of its thriving cell and gene therapy cluster of national and international significance. The successful HPO nomination was made by Hertfordshire Local Enterprise Partnership (LEP) and is expected… Read More

#News

#Diamond Pharma Services #EMA #Gene therapy #Marketing approval authorisation

Diamond Pharma Services supports MAA for ocular gene therapy

Diamond Pharma Services has provided EU regulatory, pharmacovigilance, quality and compliance support to GenSight Biologics including the preparation, authoring support, agency communication and submission of GenSight’s first marketing authorisation application (MAA) to the European Medicines Agency (EMA), for its novel ocular gene therapy LUMEVOQ.  The EMA decision is expected in… Read More

#News